Failure to Clarify, Consent, and Monitor Antipsychotic Use Resulting in Resident Hanging
Summary
The deficiency involves the facility’s failure to ensure a resident’s antipsychotic drug regimen was free from unnecessary drugs and was properly indicated, consented, and monitored. A male resident with Alzheimer’s disease, unspecified dementia with behavioral disturbance, memory deficit following cerebral infarction, and restlessness and agitation was admitted on 02/14/26. Prior to and at admission, he had been prescribed Quetiapine (Seroquel) 50 mg at bedtime as needed for insomnia, but on admission the facility entered the order on the Physician Order Sheet as Quetiapine 50 mg by mouth at bedtime for dementia. Subsequent physician and psychiatry notes documented Quetiapine 50 mg at bedtime for dementia-related agitation, while a later physician visit summary again listed Quetiapine 50 mg nightly as needed for insomnia. These records showed inconsistent and unclear indications and frequency for the antipsychotic medication. The facility also failed to obtain complete informed consent for the antipsychotic medication. The consent form for Quetiapine dated 02/14/26 did not include the date the consent was actually given and did not identify the authorized person providing consent. Although the facility’s psychotropic medication policy required informed consent from the resident or authorized representative and incorporation of psychotropic use into the care plan with suitable goals and approaches, there was no specific care plan addressing the resident’s use of antipsychotic medication. The existing care plan only addressed potential cognitive problems related to Alzheimer’s dementia and included a general intervention to administer medications as ordered and monitor for side effects and effectiveness, without specific goals, approaches, or monitoring parameters for the antipsychotic. The facility did not adequately monitor for adverse reactions, evaluate effectiveness, or document behavioral responses related to the antipsychotic medication. The attending physician’s note on 02/17/26 directed staff to monitor for sedation, EPS, and metabolic effects, and the psychiatric provider later stated that Seroquel is sedating and requires close monitoring, frequent rounding, and notification if behavior worsens. The DON also stated that care plans should be initiated for psychotropic medications and that staff should monitor for side effects and unusual behavior. However, there was no behavior management policy provided, no behavior flow sheets, and no documentation of ongoing assessment or monitoring specific to the antipsychotic’s effects. During his stay, staff described the resident as confused, wandering, and entering other residents’ rooms, with documented nighttime wandering and poor sleep, but Quetiapine 50 mg at bedtime was continued without documented reassessment of its necessity or effectiveness. On 04/03/26, the resident was found hanging with a cellphone cord around his neck, unresponsive but with a pulse, and was transferred emergently to the hospital, where records documented traumatic cardiac arrest due to hanging and ligature marks around the neck. The death certificate later recorded that he died on 04/08/26 due to complications of hanging.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.